Tagged with M

Egypt Back in June 2022, Pfizer signed a memorandum of understanding (MoU) with the Egyptian Ministry of Health (MoH) to transfer the technology for producing its pneumococcal vaccine. The fifth highest selling drug in the world in 2020, Prevnar 13 is on the World Health Organization (WHO)’s list for use in routine immunisations given…

France French mid-cap Servier has launched a new visual identity and logo and announced an ambitious 2030 growth plan with an increased focus on hard-to-treat cancers.   Servier, which is governed by a foundation, brought in EUR 4.7 billion in the 2020/21 period according to the firm’s latest annual report, and…

Italy The electoral victory of the centre-right coalition in Italy should see far-right firebrand Giorgia Meloni replace former European Central Bank President Mario Draghi as Prime Minister at the end of October 2022, becoming the first woman to ever hold the role. This spirit of change seems also to have permeated…

China A roundup of some of the biggest recent stories from Chinese pharma, including Moderna’s refusal to divulge its mRNA IP, Advanced MedTech’s acquisition of urology leader WIKKON and Menarini’s AMR deal with SciClone Pharmaceuticals.   Moderna holds onto its vaccine IP and refuses tech transfer in China (Financial Times) Moderna…

Ireland Recent announcements from Ipsen and AbbVie of multimillion Euro investments into Irish manufacturing plants underline the Celtic nation’s continuing attractiveness to pharma multinationals. While an upcoming hike in Ireland’s famously low corporate taxation rates could dampen investor enthusiasm, industry insiders are bullish on the country’s continuing attractiveness.   Banking on…

Germany A roundup of some of the biggest recent stories from German pharma, including the latest on beleaguered Bayer CEO Werner Baumann, Merck KGaA’s latest investments in France and Germany, and STADA securing the first authorized treatment in Europe for the rare kidney disease immunoglobulin A nephropathy (IgAN).   Bayer’s hunt…

Egypt Under the auspices of a wide-ranging Vision 2030 economic transformation plan, Egypt is moving towards covering the entirety of its 100 million plus population under a universal healthcare insurance scheme. Via direct presidential initiatives, the country has also made significant progress in tackling diseases like hepatitis C and breast cancer,…

Egypt Pfizer’s general manager for Egypt, Ahmed El-Shazly, comments on his return to Egypt after 19 years away, the significant opportunities ahead for the affiliate as it looks to find its place within the country’s healthcare transformation, and the noteworthy MoU signed with the government to potentially localise the production of…

Egypt Mohamed Ali Abd El Azim gives several insights into GSK’s sizeable production footprint in Egypt, how the organisation’s aims dovetail with Egypt’s healthcare transformation, and what makes him proud to work in pharma manufacturing.   Our country is improving and reshaping the healthcare industry and we as GSK have the…

Americas Latin America (LatAm) Area Lead for Astellas Sandra Ramirez outlines the Japanese company’s presence in the region, its efforts to partner with local stakeholders to improve patient access, and the consolidation of its operations in the priority market of Mexico.   LatAm as a region offers many opportunities for innovation.…

Canada Biosimilar uptake initiatives are gaining traction across Canada and have already been implemented in several provinces. Dara Jospé and Lina Bensaidane of Fasken examine the impact of these policies on patients, prescribers, and pharmacists thus far, and the implications should non-medical biosimilar switching become a nationwide norm.   In the…

China Despite the impact of the COVID-19 pandemic and the vagaries of the country’s restrictive ‘dynamic zero COVID’ policy, the Chinese pharmaceutical industry is expected to continue its remarkable trajectory up to 2025 with annual growth of 9.4 percent. Read on for five key trends to watch out for in the…